Expression of hormonal factors and extracellular matrix proteins in recurrent pleomorphic adenoma

• Grant number: 14/25173-8
• Support Opportunities: Regular Research Grants
• Start date: April 01, 2015
• End date: March 31, 2017
• Field of knowledge: Health Sciences - Dentistry
• Principal Investigator: Andresa Borges Soares
• Grantee: Andresa Borges Soares
• Host Institution: Centro de Pesquisas Odontológicas São Leopoldo Mandic. Faculdade São Leopoldo Mandic (SLMANDIC). Sociedade Regional de Ensino e Saúde S/S Ltda (SRES). Campinas , SP, Brazil

Abstract

Pleomorphic adenoma (PA) is the most common neoplasm of the salivary gland and, despite being classified as benign, it is capable of recurrence (RPA). RPA presents a challenge for surgeons in terms of treatment, due to the high probability of further recurrence and an increased risk of malignant transformation. Unfortunately, few studies on RPA are available in the literature. Extracellular matrix proteins have been extensively associated with tumor biology. Hormonal factors have also been used as adjuvant therapies and prognostic markers in various neoplasms. The aim of this study is to investigate the role of fibronectin, tenascin, estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth receptor-2 (HER-2) in PA, RPA and RPA with malignant transformation (TRPA). The expression of these proteins will be evaluated using immunohistochemistry in 20 cases of PA, 20 cases of RPA and 03 cases of TRPA. HER2 gene expression will be quantified using in situ hybridization. (AU)

Scientific publications

(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)

DE SOUZA, ANA AMELIA; ALTEMANI, ALBINA; DE ARAUJO, NEY SOARES; TEXEIRAI, LUCAS NOVAES; DE ARAUJO, VERA CAVALCANTI; SOARES, ANDRESA BORGES. Estrogen Receptor, Progesterone Receptor, and HER-2 Expression in Recurrent Pleomorphic Adenoma. CLINICAL PATHOLOGY, v. 12, SEP 2019. (14/25173-8)